LENZ THERAPEUTICS, INC. Research and Development Expense
LENZ THERAPEUTICS, INC. (LENZ) reported Research and Development Expense of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $3.79M, a 41.23% decline year-over-year.
- LENZ THERAPEUTICS, INC. research and development expense for fiscal 2025 was $18.67M, a 37.35% decline from fiscal 2024.
- LENZ THERAPEUTICS, INC. research and development expense for fiscal 2024 was $29.80M, a 49.92% decline from fiscal 2023.
- LENZ THERAPEUTICS, INC. research and development expense for fiscal 2023 was $59.50M, a 18.25% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. research and development expense for fiscal 2022 was $72.79M, a 91.89% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $3.79M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $3.79M derived: sum of 3 quarters · filed 2026-05-11 | $12.85M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $3.79M derived: sum of 2 quarters · filed 2026-03-24 | $12.85M derived: sum of 3 quarters · filed 2026-08-11 | $18.67M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $3.79M 10-Q · filed 2025-11-05 | $12.85M derived: sum of 2 quarters · filed 2026-08-11 | $18.67M 10-Q · filed 2025-11-05 | $24.54M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $9.06M 10-Q · filed 2026-08-11 | $14.88M 10-Q · filed 2026-08-11 | $20.75M derived: sum of 3 quarters · filed 2026-08-11 | $27.20M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $5.82M 10-Q · filed 2026-05-11 | $11.69M derived: sum of 2 quarters · filed 2026-05-11 | $18.14M derived: sum of 3 quarters · filed 2026-05-11 | $25.08M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $12.32M derived: sum of 2 quarters · filed 2026-03-24 | $19.26M derived: sum of 3 quarters · filed 2026-03-24 | $29.80M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | $6.45M 10-Q · filed 2025-11-05 | $13.40M derived: sum of 2 quarters · filed 2025-11-05 | $23.93M 10-Q · filed 2025-11-05 | $43.47M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $6.95M 10-Q · filed 2025-07-30 | $17.48M 10-Q · filed 2025-07-30 | $37.02M derived: sum of 3 quarters · filed 2025-07-30 | $54.02M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | $10.54M 10-Q · filed 2025-05-07 | $30.07M derived: sum of 2 quarters · filed 2025-05-07 | $47.08M derived: sum of 3 quarters · filed 2025-05-07 | $59.72M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $19.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $36.54M derived: sum of 2 quarters · filed 2025-03-19 | $49.18M derived: sum of 3 quarters · filed 2025-03-19 | $59.50M 10-K · filed 2025-03-19 | $32.14M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $17.00M 10-Q · filed 2024-11-06 | $2.38M 10-Q · filed 2023-11-13 | $29.64M derived: sum of 2 quarters · filed 2024-11-06 | $39.97M 10-Q · filed 2024-11-06 | $32.14M 10-Q · filed 2023-11-13 | $58.43M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $12.64M 10-Q · filed 2024-08-14 | $13.51M 10-Q · filed 2023-08-14 | $22.96M 10-Q · filed 2024-08-14 | $29.75M 10-Q · filed 2023-08-14 | $41.43M derived: sum of 3 quarters · filed 2024-08-14 | $59.73M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $10.32M 10-Q · filed 2024-05-08 | $16.24M 10-Q · filed 2023-05-11 | $28.79M derived: sum of 2 quarters · filed 2024-05-08 | $47.09M derived: sum of 3 quarters · filed 2024-05-08 | $64.87M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $36.76M derived: sum of 2 quarters · filed 2024-02-27 | $54.54M derived: sum of 3 quarters · filed 2024-02-27 | $72.79M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $18.30M 10-Q · filed 2023-11-13 | $36.08M derived: sum of 2 quarters · filed 2023-11-13 | $54.33M 10-Q · filed 2023-11-13 | $65.53M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $17.78M 10-Q · filed 2023-08-14 | $36.02M 10-Q · filed 2023-08-14 | $47.23M derived: sum of 3 quarters · filed 2023-08-14 | $55.91M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $18.25M 10-Q · filed 2023-05-11 | $29.45M derived: sum of 2 quarters · filed 2023-05-11 | $38.13M derived: sum of 3 quarters · filed 2023-05-11 | $50.80M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $19.89M derived: sum of 2 quarters · filed 2023-03-20 | $32.55M derived: sum of 3 quarters · filed 2023-03-20 | $37.93M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | $8.68M 10-Q · filed 2022-11-09 | $21.35M derived: sum of 2 quarters · filed 2022-11-09 | $26.73M 10-Q · filed 2022-11-09 | $33.12M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $12.67M 10-Q · filed 2022-08-11 | $18.04M 10-Q · filed 2022-08-11 | $24.43M derived: sum of 3 quarters · filed 2022-08-11 | $26.74M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $5.38M 10-Q · filed 2022-05-12 | $11.77M derived: sum of 2 quarters · filed 2022-05-12 | $14.08M derived: sum of 3 quarters · filed 2022-05-12 | $14.50M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $8.70M derived: sum of 2 quarters · filed 2022-03-21 | $9.12M derived: sum of 3 quarters · filed 2022-03-21 | $9.12M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $2.31M 10-Q · filed 2021-11-10 | $2.73M derived: sum of 2 quarters · filed 2021-11-10 | $2.73M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $423.00K 10-Q · filed 2021-08-12 | $423.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |